Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

Yet the tennis legend knows firsthand how harshly people judge the use of GLP-1 drugs for weight loss. Now, she’s using her ...

As someone who had built her career on grit and hard work, Williams hesitated before exploring weight-loss medications ...

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview.

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.” ...

It is through this company that she gets prescribed Zepbound, a GLP-1 medication. Williams admitted to initially being ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Columnist Teri Sforza writes that studies have found that semaglutide reduced alcohol intake, binge drinking and relapse ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.